Immunovant (IMVT) Share-based Compensation (2019 - 2026)

Immunovant has reported Share-based Compensation for 8 years, with the latest figure at $11.1 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 4.67% year-over-year to $11.1 million; the trailing twelve-month figure through Mar 2026 stood at $55.7 million (up 12.6% YoY), and the FY2026 full-year result was $55.7 million, up 12.6% from the prior year.
• Share-based Compensation for Q1 2026 stood at $11.1 million, down from $12.7 million in the prior quarter.
• The five-year high for Share-based Compensation was $18.5 million in Q2 2025, with the low at $7.5 million in Q1 2023.
• Historically, Share-based Compensation has averaged $11.2 million across 5 years, with a median of $11.1 million in 2026.
• Annual changes were most pronounced in 2022 — Share-based Compensation surged 116.16% — and 2023, when it slumped 36.39%.
• Immunovant's Share-based Compensation stood at $8.9 million in 2022, then rose by 14.75% to $10.2 million in 2023, then rose by 14.01% to $11.7 million in 2024, then advanced by 9.12% to $12.7 million in 2025, then slipped by 12.38% to $11.1 million in 2026.
• The last three Share-based Compensation figures came in at $11.1 million (Q1 2026), $12.7 million (Q4 2025), and $13.4 million (Q3 2025), per Business Quant data.